AVEO Pharmaceuticals to present preclinical data from translational research platform at AACR 2010

Apr 13 2010

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that preclinical data from its translational research platform and antibody pipeline will be presented during six poster sessions at the American Association for Cancer Research (AACR) 101^st Annual Meeting 2010 being held April 17-21, 2010, in Washington, D.C.

“We look forward to sharing with our peers in the oncology community preclinical data from AVEO's translational research platform and antibody discovery programs”

"We look forward to sharing with our peers in the oncology community preclinical data from AVEO's translational research platform and antibody discovery programs," stated Murray O. Robinson, Ph.D., senior vice president, translational medicine, AVEO Pharmaceuticals. "The data being presented at AACR show the maturation of our Human Response Platform™ which continues to play an important role in our clinical development and antibody discovery programs."

SOURCE AVEO Pharmaceuticals, Inc.